摘要：In August 1997, a workshop was convened by the National Centre for Immunisation Research andSurveillance of Vaccine Preventable Diseases to consider current issues in the use of pertussisvaccines and implications for the Australian immunisation schedule. Topics covered included thehistory, efficacy and reactogenicity of whole-cell and acellular vaccines and vaccine schedules.Acellular pertussis vaccine is preferred by the National Health and Medical Research Council forthe primary course as well as the 18 month and 4-5 year old childhood doses. At the time of theworkshop, a 3-component acellular vaccine (DTPa) had been approved (licensed) in Australia forall doses in the childhood schedule. It was the first vaccine subject to a cost-effectiveness evalu ation under the new vaccine funding arrangements. Issues considered in the evaluation of thecost-effectiveness of the vaccine were discussed. These included comparative efficacy, adverseevents and compliance, and the question of community as well as individual benefit from the use ofthe vaccine
